Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 9/20 | 0.41 |
| ▸ | CNR1 | P21554 | 7/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16846967 | 0.86 | PTPRC (0.48) | PTPRCPTPN2PTPN1CXCR2ALDH1A1 | |
| SCHEMBL10189644 | 0.81 | PTPRC (0.53) | PTPRCPTPN2PTPN1CXCR2ALDH1A1 | |
| SCHEMBL10189466 | 0.79 | ALDH1A1 (0.41) | PTPN2PTPN1ALDH1A1TSHRCNR2 | |
| SCHEMBL351385 | 0.77 | ADORA1 (0.55) | PTPRCPTPN2PTPN1ALDH1A1TSHR | |
| SCHEMBL10190438 | 0.77 | KMT2A (0.49) | ALDH1A1TSHRCNR2CNR1MAPT | |
| SCHEMBL14648860 | 0.77 | KMT2A (0.46) | ALDH1A1CNR2CNR1KIF11MAPT | |
| SCHEMBL8288837 | 0.68 | PTPRC (0.52) | PTPRCPTPN2PTPN1CXCR2ALDH1A1 | |
| SCHEMBL13151117 | 0.66 | PTPRC (0.53) | PTPRCPTPN2PTPN1CXCR2ALDH1A1 | |
| SCHEMBL15139322 | 0.66 | CNR2 (0.42) | ALDH1A1TSHRCNR2CNR1KIF11 | |
| SCHEMBL12057591 | 0.66 | ALDH1A1 (0.58) | ALDH1A1TSHRCNR2CNR1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | PTPRC 1727/4885PTPN2 2318/4885PTPN1 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.